GlassScriptPhysician profile
Peter Douglas Stephan
NPI 1548266307
$4,917.42
in general payments reported to CMS, 2019-2025
20 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $396 · 2021: $1,190 · 2022: $577 · 2023: $1,026 · 2024: $645 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,475.93 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,026.53 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $813.30 | 2019-2024 | Ubrelvy, Qulipta |
| Abbott Laboratories | $366.06 | 2021-2024 | Freestyle Libre 3, Freestyle Libre |
| Lilly USA, LLC | $200.36 | 2019-2023 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $141.03 | 2019 | |
| Pfizer INC. | $137.56 | 2019-2023 | |
| Corium, LLC | $125.00 | 2022 | |
| Dexcom, INC. | $124.99 | 2023 | Dexcom G7 Gss (161) |
| Corcept Therapeutics | $118.80 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $115.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.00 | 2019 | |
| Aytu Biopharma, INC. | $35.15 | 2019 | |
| Astellas Pharma US INC | $28.32 | 2019 | |
| Assertio Therapeutics, INC. | $27.74 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.93 | 2019 | |
| Allergan, INC. | $20.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $12.46 | 2019 | |
| Glaxosmithkline, LLC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Stephan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.